Company Description
AmerisourceBergen is the source for many of North America's pharmacies and health care providers. The company serves as a go-between for...
Key AmerisourceBergen Financials
| Company Type | Public - NYSE: ABC Main Headquarters |
|---|---|
| Fiscal Year-End | September |
| 2007 Sales (mil.) | $66,074.3 |
| 2007 Employees | 11,300 |
More AmerisourceBergen Financials (11 pages)
Latest AmerisourceBergen Jobs jobs by Indeed
Rankings
- #28 in FORTUNE 500
- S&P 500
Competition
Competitive Landscape for Professional Services
Demand is driven heavily by the health of the US economy and particularly by corporate profits. While some professional services are necessary for the normal functioning of most...
Read more about AmerisourceBergen's competition across multiple industries
Top AmerisourceBergen Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
AmerisourceBergen Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Richard C. Gozon | Network | E-mail |
| President, CEO, and Director | R. David (Dave) Yost | Network | E-mail |
| EVP and CFO; COO, Drug | Michael D. DiCandilo | Network | E-mail |
More AmerisourceBergen Executives
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current AmerisourceBergen News
- AmerisourceBergen Corporation (ABC) Corporate Event Announcement Notice [Wall Street Horizon] (27 Jun 2008 20:39:00 EDT)
- AmerisourceBergen Corporation (ABC) Corporate Event Announcement Notice [Wall Street Horizon] (26 Jun 2008 20:36:00 EDT)
- S&P reaffirms ratings for Arab Banking Corporation [Middle East & North Africa Business Report (Amman] (25 Jun 2008 04:00:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.